[Federal Register Volume 63, Number 201 (Monday, October 19, 1998)]
[Notices]
[Pages 55886-55887]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-27961]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: 21 Substituted 
Progesterone Derivatives as New Anti-Progestational Agents

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
an exclusive license worldwide to practice the invention embodied in: 
U.S. Patent Application Serial No. 60/016, 628, filed May 1, 1996 
entitled, ``21 Substituted Progesterone Derivatives as New Anti-
Progestational Agents'' to Zonagen, Inc., having a place of business in 
Houston, TX. The patent rights in this invention have been assigned to 
the United States of America.

DATES: Only written comments and/or application for a license which are 
received by the NIH Office of Technology Transfer on or before December 
18, 1998 will be considered.

ADDRESSES: Requests for a copy of the patent applications, inquiries, 
comments and other materials relating to the contemplated license 
should be directed to: Dennis H. Penn, Pharm.D., Technology Licensing 
Specialist, Office of Technology Transfer, National Institutes of 
Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; 
Telephone: (301) 496-7056, ext. 211; Facsimile: (301) 402-0220.

SUPPLEMENTARY INFORMATION: In an effort to develop an efficacious 
treatment for human reproductive disorders this invention describes 21 
progesterone analogs possessing potent antiprogestational activity with 
minimal antiglucocorticoid activity. These compounds may have utility 
in treating human reproductive disease and certain hormone sensitive 
tumors.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective

[[Page 55887]]

exclusive license may be granted unless, within 60 days from the date 
of this published Notice, NIH received written evidence and argument 
that establishes that the grant of the license would not be consistent 
with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
    The field of use may be limited to the use of the invention for the 
development of pharmaceutical compounds to treat drug human 
reproductive disorders and hormone sensitive tumors.
    Properly filed competing applications for a license filed in 
response to this notice will be treated as objections to the 
contemplated license. Comments and objections submitted in response to 
this notice will not be made available for public inspection, and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: October 13, 1998.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer.
[FR Doc. 98-27961 Filed 10-16-98; 8:45 am]
BILLING CODE 4140-01-M